MedTrace Logo

Alimta Plus Gemcitabine for Advanced Sarcoma

NCT00860015 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-08-25

Study results available
· View outcomes & findings →

Summary

In patients with unresectable soft tissue sarcoma, what is the response rate if treated with Alimta and gemcitabine?

Conditions

  • Sarcoma, Soft Tissue

Interventions

DRUG

Alimta

500 mg/m2 via IV over 10 minutes A chemotherapy drug with indications to treat pleural mesothelioma and non-small cell lung cancer.

DRUG

Gemcitabine

1000 mg/m2 via IV over 90 minutes A nucleoside analog used as chemotherapy.

Sponsors & Collaborators

Principal Investigators

  • Robert N Taub, MD, PhD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-08-31
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00860015 on ClinicalTrials.gov